Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant

Sustained release of ganciclovir and foscarnet from biodegradable scleral plugs for the treatment of cytomegalovirus retinitis

“…Treatment with ganciclovir implants has gained good success at the control of CMV retinitis progression as compared to IV ganciclovir [31]. But the implantation procedure includes large pars plana incision to insert the implant, and hence, the disruption of vitreous base may increase the risk of retinal detachment [32].…”

A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases

“…51,79 The Vitrasert 1 reservoir-type device (Chiron Vision Inc., Irvine, CA), composed of drug and polymeric coats of polyvinyl alcohol (PVA) and ethylene vinyl acetate (EVA). The device is implanted in patients requiring the treatment of CMV-R. PVA, a permeable polymer regulates the rate of ganciclovir permeation through the device (Fig.…”

The Role of Ganciclovir in Transplantation

“…The ganciclovir implant (Vitrasert ® , Bausch & Lomb) is highly successful at preventing the progression of CMV retinitis, and was found to be significantly more effective than IV ganciclovir at slowing this progression [40] . Despite a greater decline in the progression of CMV retinitis, the implantation alone was unsuccessful at preventing extraocular CMV infections or infection in the contralateral eye.…”